Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading

Rare disease has never been more central to pharmaceutical strategy. This week produced a landmark approval for one of the world's rarest conditions, a new drug class in a well-established blood cancer, a stepped licensing deal for a rare genetic lung disease, and a major biosimilar collaboration involving a Chinese biotech. Taken together, they reflect a set of durable trends that are reshaping how drugs get developed, partnered, and approved. Here is what you need to know.